Oncology Medical News about Lymphoma Lymphoma, Large B-Cell, Diffuse

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
Leukemia and Lymphoma, 11/04/09

Derenzini E et al. – Young patients (aged 18–60 years) with good–prognosis diffuse large B–cell lymphoma (DLBCL) [0 and 1 risk factor according to age–adjusted international prognostic index (aa–IPI)] are distinguished from patients with poor–prognosis. R–MACOP–B regimen followed by involved–field radiation on bulky presentation is safe and very effective in the treatment of young patients with low–risk DLBCL.

<< Previous
D-dimer as a possible prognostic marker of operable hormone...

Next >>
Extranodal natural killer/T-cell lymphoma: current concepts in...

Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach
Hematological Oncology, 10/27/09 Relevance Score: 95%

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy
Annals of Oncology, 11/16/09 Relevance Score: 94%

High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma
Leukemia and Lymphoma, 10/30/09 Relevance Score: 94%

Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
Annals of Oncology, 10/30/09 Relevance Score: 94%

Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
Journal of Clinical Oncology, 10/02/09 Relevance Score: 94%